# CinCor Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cincor-pharma

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.cincor.com
- Total disclosed funding: $193M
- Latest round: Series B (Sep 22, 2021)
- Investors on record: 14

## About

Based in Ohio, US, and founded in 2018, CinCor Pharma, Inc. operates as a clinical-stage cardiorenal therapeutics company. Catherine Pearce is a co-founder of the company. Marc de Garidel is the CEO of the company as of 2021. In January 2023, AstraZeneca acquired CinCor Pharma, Inc. for approximately USD 1.3 billion. The transaction was completed in February 2023.

The company researches and develops biopharmaceuticals for the treatment of cardio-renal diseases. CIN-107, a highly selective oral small molecule inhibitor of aldosterone synthase, is the company's lead asset and is being tested in clinical trials for the treatment of resistant hypertension and primary aldosteronism.

CinCor Pharma, Inc. intends to use the series B funding in October 2021 for the completion of the ongoing brigHTN Phase 2 clinical trial and Phase 2 Spark trial and expand the potential utility of CIN-107 into other indications including primary aldosteronism and CKD.

## Funding rounds

- Series B, Sep 22, 2021, $143M — Sofinnova Partners, Sofinnova Investments, General Atlantic, 5AM Ventures, Adage Capital Management, Lilly Asia Ventures, Omega Funds, VenBio, RTW Investments, BVF Partners, Rock Springs Capital, Perceptive Advisors, CinRx Pharma, LLC, Sixty Degree Capital
- Series A, May 14, 2019, $50M — Sofinnova Partners, Sofinnova Investments, 5AM Ventures

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series B
- Adage Capital Management — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- Rock Springs Capital — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- CinRx Pharma, LLC — Series B
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series B